Chronic kidney disease (CKD) has become a worldwide public health priority and is estimated to affect approximately 12% of the global population. CKD is associated with an increased cardiovascular morbidity, premature mortality, and a substantial economic burden.
Introduction
Chronic kidney disease (CKD) is a worldwide public health priority and is estimated to currently affect between 11-13% of the global population. 1 CKD is associated with increased cardiovascular morbidity, premature mortality and a substantial healthcare cost. 2, 3 Gradual decline in kidney function in individuals with CKD involves dysfunction of several biological pathways, including altered cellular metabolism, nitrogen balance and protein metabolism changes, insulin resistance and increased production of mediators of inflammation and oxidative stress. [4] [5] [6] [7] Increased generation of reactive oxygen species (ROS) has been observed at throughout progressive stages of CKD and it has been suggested that this may be the result of mitochondrial dysfunction. 8 Mitochondria are responsible for generation of adenosine triphosphate (ATP) to provide energy to eukaryotic cells via a series of oxidative phosphorylation (OXPHOS) reactions known as the electron transport chain (ETC). Mitochondria also regulate cellular metabolism via heme and steroid synthesis, generating ROS, establishing the membrane potential and controlling calcium and apoptotic signalling. 9, 10 It is thought that these cellular powerhouses ( Fig. 1 ) originated through an endosymbiotic relationship with an α-proteobacterium. 11 Although many mitochondrial genes are now located on nuclear chromosomes these organelles contain their own circular genome reminiscent of their bacterial ancestors. 12, 13 By transferring a substantial amount of genetic material to the nuclear genome the size of the mitochondrial genome is greatly reduced, which may impart a replicative advantage and reduce the likelihood of incurring disadvantageous mutations, thus reinforcing the idea of a synergistic relationship between these two genomes. 14 Among human body organs, the kidneys are second to the heart in terms of energy demands, mitochondrial content and oxygen consumption. 15, 16 This is necessary to produce the energy required for removal of waste from blood, reabsorption of nutrients, regulation of electrolyte and fluid balance, maintenance of acid-base homeostasis, and regulation of blood pressure. 17 Mitochondria also provide the energy required by Na + -K + -ATPase to create ion gradients across the cellular membrane and to facilitate active transport in the proximal tubule, the loop of Henle, the distal tubule and the collecting duct to allow ion reabsorption and excretion. 18 Energy demands, and in turn mitochondrial content are much higher in the proximal tubules compared with the glomerulus as glomerular filtration is a passive process whereas the proximal tubules require a large variety of active transport mechanisms in order to reabsorb 80% of the filtrate that passes through the glomerulus. 19 Because of these high energy requirements, mitochondrial dysfunction in the kidneys may severely impact renal health and has previously been implicated in CKD development.
CKD is typically defined as kidney structure or function abnormalities persisting for more than three months and impacting on the health of the individual. 20 As the body ages the kidneys undergo agerelated structural changes along with a reduction in functional capacity. In adults over 35 years, kidneys gradually lose functional nephrons and decrease in size so that by 80 to 85 years old many individuals will have lost up to 30% of total kidney mass. 21 Although many older people with reduced kidney mass will continue to have normal kidney function there is a reduction in the "margin of safety" which in turn will impact on the kidneys' ability to respond to stress placed upon remaining nephrons such as infection or reduced blood flow. 21 Many elderly people will exhibit a low glomerular filtration rate (GFR) but without any specific kidney disease. It is therefore important to understand the underlying genetic causes of kidney disease and decreasing renal function in order to design more effective therapies and reduce the associated healthcare burden. 22, 23 Persistent reduced kidney function, with or without proteinuria measured by albumin creatinine ratio (ACR), is indicative of CKD and is associated with damage to kidney tubules and glomeruli. Although the underlying cause of reduced renal function in CKD may vary between individuals, there are several pathways involved with CKD development including accumulation of extracellular matrix (ECM) proteins in the glomerulus, interstitial fibrosis, tubular atrophy and inflammation. Over the last decade, several genetic risk factors have been identified and robustly associated with CKD. [24] [25] [26] [27] 
Mitochondrial Genetics
Genes required for normal mitochondrial function are found on both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). The mitochondrial genome is a circular double stranded DNA molecule composed of 16,569 base pairs harbouring 37 genes encoding 13 key proteins of the ETC along with two rRNAs and 22 tRNAs ( Fig. 1 ). 12 In contrast to nDNA, mtDNA lacks introns and non-coding intergenic regions, apart from a small regulatory region between the mitochondrial genes for phenylalanine and proline tRNAs known as the non-coding region (NCR). This 1.1 kb stretch of DNA frequently contains a third single strand of DNA 650 nucleotides long (7S DNA) which forms a displacement-loop, or D-loop 28 , postulated to be an mtDNA replication intermediate [29] [30] [31] , facilitating more open conformation of the mtDNA molecule, allowing proteins involved in replication or transcription to bind and regulate these activities. 32, 33 Although the exact mechanism of replication in mtDNA is not yet fully understood, a number of nuclear encoded enzymes are essential to this process. [34] [35] [36] [37] [38] [39] In humans, mtDNA passes to offspring through maternal gametes. As each mitochondrion contains multiple copies of maternally inherited mtDNA, and each cell contains many mitochondria, it is possible for mutations to occur during replication which will affect some mtDNA molecules but not others; this phenomenon is known as heteroplasmy and contributes to disease development. 40 During an individual's lifetime the actions of ROS and the resulting mtDNA mutations are thought to be directly involved in various disease mechanisms and the process of aging. 41 There are at least 2,526 autosomal genes involved with mitochondrial function. Many nuclear encoded mitochondrial genes (NEMGs) code for proteins which are synthesised on ribosomes in the cytosol, migrate to the mitochondria, and are transported across the mitochondrial membrane based on the presence of a specific N-terminal presequence. 42 Other NEMGs do not code directly for mitochondrial components but regulate the expression of a range of genes which are essential for normal mitochondrial biogenesis and function.
Mitochondria and nuclear gene interactions
Mitochondrial dysfunction may be due to inherited germline or acquired somatic mutations. For example, acquired damage to tubular mitochondria alters mitochondrial dynamics, mitophagy and biogenesis in acute kidney injury which is risk factor subsequently for CKD. 43 RecQ-like helicase 4 (RECQL4) is a dynamic protein important for protein-protein interactions in nDNA replication but also localises to the mitochondrion where it interacts with POLγ in order to maintain mtDNA integrity. 44 RECQL4 mutations result in increased mtDNA copy number and mitochondrial dysfunction. 45 This protein may also act to regulate p53 tumour mitochondrial transport while RECQL4 dysfunction may decrease p53 activity. 46 Data from immunofluorescence microscopy suggest that DNA2 molecules are mainly found in mitochondria where they have been shown to interact with Polγ and Twinkle. 47, 48 These interactions may be important in repairing oxidative lesions in mtDNA, mtDNA maintenance and protection against mtDNA related diseases. 48, 49 Petite integration frequency 1 (PIF1) is a member of the superfamily 1 helicase family that acts in both nuclei and mitochondria. [50] [51] [52] [53] [54] [55] [56] A DExH-box helicase known as suppressor of Var1 3-Like Protein 1 (SUV3) is thought to be indirectly involved in mtDNA stability and copy number regulation. 57 SUV3 is important in regulating mitochondrial RNA levels and may also interact with nDNA replication and repair factors in the nucleus. [58] [59] [60] [61] These interactions between mtDNA and nDNA highlight the symbiotic relationship between mitochondrial organelle and the nucleus. Due to this relationship, dysfunction of genes in mtDNA or nDNA can have devastating consequences and mitochondrial dysfunction is strongly implicated in kidney disease.
Mitochondria and CKD
More than 250 genes involved with mitochondrial energy metabolism have been associated with human disease 62 and this mitochondrial damage may occur due to direct mtDNA insult or NEMG defects. 63 Damage or mutations in mtDNA may lead to primary defects in mitochondrial OXPHOS due to dysfunction of the ETC components, which can result in a range of clinical symptoms involving several different organs broadly termed as, 'mitochondrial diseases'. Mutations in mtDNA often have a greater functional impact than variants in nuclear-encoded mitochondrial genes; several mtDNA genes are known to affect kidney function (Table 1) .
For example, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome are mitochondrial cytopathies resulting from defects in MT-ND1 and MT-ND5 which encode for complex I proteins, as well as MT-TH, MT-TL1, and MT-TV which code for mitochondrial tRNAs. 64 NEMG insults may also lead to OXPHOS defects, abnormal protein translation, and lower mtDNA copy number. 65 Traditional mitochondrial diseases often include renal complications, due to an mitochondrial abundance as well as kidney high energy demands e.g. defects in CoQ 10 synthesis and the mtDNA 3243 A>G mutation are known to cause renal complications including focal segmental glomerulosclerosis. 43, [66] [67] [68] [69] [70] [71] [72] Tubular defects are the most common renal manifestation of
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Copyright 2019 www.spg.ltd 5 mitochondrial disorders from mutations in mtDNA or NEMGs. Mitochondrial isoleucine tRNA gene (tRNA Ile ) mutations have been associated with familial hypercholesterolemia and hypomagnesaemia. 73 Fanconi syndrome which is secondary to kidney tubular dysfunction has been linked with mutations in the gene EHHADH. 74 Five nuclear genes (COQ5, COX6A1, GATC, TOP1MT and PARCRG) have been linked to kidney disease in people with type 1 diabetes, across multiple cohorts. 75 Thirty-eight NEMGs are reported to be involved with CKD development (Table 2 ; Supplementary  Table 1) , with many having important roles in maintaining mitochondrial function and renal health. NEMGs dysregulation because of acquired or inherited mutations can affect several pathways which may initiate a vicious cycle aggravating renal damage and leading to CKD (Fig. 2 ). Many NEMGs are essential for mitochondrial biogenesis and normal mitochondrial function, particularly PPARGC1A which regulates TFAM, COX6C, COX7C, UQCRH, MCAD, SIRT3, and NRF1. 76 PPARGC1A and its downstream targets are reported to be downregulated in peripheral blood mononuclear cells of CKD patients. PPARGC1A induction by ROS may act as a protective adaption to reduce further ROS generation. 77 Other genes involved with mitochondrial biogenesis are upregulated in CKD in response to increased ROS production, these include NFE2L2 (regulated by PPARGC1A), SOD2, Complex 1 components (NDUFS5, NDUFA6, NDUFA1 and NDUFB1), UQCRH, UQCRB, ATP5I, ATP5J, and ATP5O. [77] [78] [79] Upregulation of these genes may be an attempt to compensate for increased ROS generation resulting from OXPHOS dysfunction. Genes coding for complex IV 6C and 7C subunits (COX6C and COX7C) were also seen to be upregulated in CKD, however, complex IV activity was reduced due to chronic oxidative stress and oxidant injury resulting from OXPHOS system inhibition. 11 Damage to nDNA and mtDNA can arise from various sources (Supplementary Table 2 ) and DNA damage may compromise or bypass repair mechanism increasing the frequency of mutations.
Several studies have investigated SNPs associated with chronic kidney disease ( Table 3 ). Damage to both NEMGs and mtDNA genes may have an impact on mitochondrial function due to ineffectual clearance of ROS which may further exacerbate mitochondrial damage and lead to increased ROS production due to AIFM1 80 downregulation and NOX4 upregulation. 81, 82 This vicious cycle of ROS production results in oxidative stress within the mitochondria leading to ATG5 and BECN1 downregulation, 83 which may lead to abnormal or impaired autophagy which in turn leads to further ROS generation, dysregulated mitochondrial fission and reduced mitochondrial function. [83] [84] [85] BNIP3 is an important mediator of mitophagy and upregulation of this gene has been associated with sarcopenia in CKD along with decreased mtDNA copy number and reduced mitochondrial function. 86 The intrinsic pathway of apoptosis has also been implicated in CKD. Downregulation of the antiapoptotic protein BCL-xL coded for by BCL2L1 combined with upregulation of pro-apoptotic BAX and BAK1 leads to increased apoptosis and depolarisation of the outer mitochondrial membrane in proximal tubular cells. BAX upregulation and BCL2L1 downregulation activates the intrinsic apoptotic pathway, permeabilising the inner mitochondrial membrane leading to cytochrome C release. [87] [88] [89] Science Publishing Group Copyright 2019 www.spg.ltd 6
Uncontrolled apoptosis may eventually lead to inflammation and fibrosis commonly observed in CKD. Experimental CKD models have shown increased expression of several genes involved with inflammation and fibrosis. TGFβ expression increases in response to apoptosis in primary tubular cells exposed to albumin stimulating ECM formation and the extrinsic apoptotic pathway. 90,91 PPARγ upregulation is common in several forms of renal disease and affects renal parenchymal cells stimulating various pathways important in CKD development including fibrotic, inflammatory, immune, proliferative, reactive oxygen and mitochondrial injury pathways. 92 NLRP3 upregulation and downstream targets CASP1, IL-18, and IL-1β are upregulated in CKD in response to mitochondrial ROS generation. Activation of the NLRP3 inflammasome leads to increased ECM deposition, apoptosis and fibrosis of renal cells. NLRP3 knockout or ROS inhibition reduce mitochondrial dysfunction, reduce apoptosis, decrease ECM deposition and protect against renal fibrosis. [93] [94] [95] [96] Mitochondrial dysfunction resulting from inherited or acquired genetic defects may lead to development of various forms of kidney disease such as acute kidney injury, diabetic nephropathy, glomerular diseases, tubular diseases and CKD. 43, 97, 98 In summary, mitochondrial dysfunction and OXPHOS defects may increase ROS generation and reduce ATP production which leads to increased oxidative stress which may lead to uncontrolled autophagy, mitophagy and further ROS production. Mitochondrial dysfunction, ROS generation and the resulting dysregulation of autophagic mechanisms may also lead to an upregulation of the intrinsic pathway of apoptosis which in turn leads to inflammation and fibrosis in the renal tubules, glomerulus and podocytes. This damage may then generate further autophagy leading to apoptosis, fibrosis and inflammation with further podocyte function reduction eventually leading to irreversible podocyte injury and progression to CKD.
NEMGs involved with podocyte function may play a key role in the progression of CKD. Cathepsin D, coded for by CTSD, is a lysosomal proteinase involved with lysosomal degradation, autophagic degradation and contributes to maintaining podocyte homeostasis. CTSD may be downregulated or inactivated in CKD and loss of this protein leads to impaired autophagy, resulting in the accumulation of toxic subunit c-positive lipofuscins and slit diaphragm proteins followed by apoptotic cell death. 99 ITCH expression is increased in mouse models of kidney disease. 100 This gene is regulated by the Src kinase Fyn and modulates various signalling pathways including TGFβ and EGF through ubiquitin and non-ubiquitin mediated mechanisms. [101] [102] [103] [104] Interactions with Fyn, TGFβ and related signalling molecules may suggest a role of ITCH in regulating glomerular sclerosis and podocyte function. 100 Downregulation of NRP2 was observed in animal models of kidney disease and NRP2 knockout mice displayed progressive glomerular damage when exposed to a podocyte toxin. 100, 105 modifications resulting from an adverse in utero environment have been implicated in increased risk of several diseases such as cardiovascular disease, hypertension, type 2 diabetes mellitus, obesity and renal disease. [115] [116] [117] [118] [119] [120] A systematic review by White and colleagues 121 reported that low birth weight individuals (<2.5 Kg at birth) have an increased CKD risk of in adulthood. Epigenetic changes are also acquired throughout life often in response to adverse conditions such as the high-glucose environment experienced in diabetes mellitus. 122 The role of epigenetic modifications in kidney disease have previously been discussed in detail elsewhere [123] [124] [125] [126] and methylation of nuclear DNA and histone modifications are known to influence CKD development, particularly in patients with diabetes. 127, 128 Genes involved with renal development and renal fibrosis have also been found to be differentially methylated in persons with CKD. [129] [130] [131] [132] [133] [134] [135] Amongst these differentially methylated genes the top canonical pathways included oxidative phosphorylation and mitochondrial dysfunction. 135 DNA hypermethylation was also observed on the PGC-1α promotor region in diabetic patients and was inversely correlated with mitochondrial content. 136, 137 Recent studies using cell lines devoid of mitochondria demonstrated that depletion of mitochondrial DNA can lead to abnormal CpG methylation patterns and restoration of mtDNA in these cells partially reverse these changes. 138 This highlights the ability of mitochondria and nDNA to interact through both genetic and epigenetic mechanisms. Due to this complex interaction, mitochondrial dysfunction will affect both the nuclear and the epi-genome. Resulting bioenergetics failure is implicated in a number of energy deficiency diseases particularly in tissues which rely on high energy flux including brain, heart, muscle, renal, and endocrine systems. 139, 140 Within the context of renal disease, mitochondrial proteins ability to cause epigenetic modifications has been demonstrated through the ability of mitofusion 2 to abate histone acetylation in the promoter region of collagen IV through a reduction in ROS generation, in turn reducing collagen IV expression in streptozotocin-induced diabetic rats. [141] [142] [143] [144] Historically, there was much debate surrounding the mtDNA ability to undergo epigenetic changes. [145] [146] [147] [148] [149] [150] [151] However, in 2011 advances in methodology and sensitivity demonstrated the presence of methylated bases in human mtDNA. 152 Shock and colleagues showed that a DNMT1 transcript variant was present inside mitochondria where it is capable of modifying transcription of the mitochondrial genome. 153 Also around this time, Chestnut and colleagues observed DNMT3a in mitochondria of mouse and human tissue, providing evidence that DNA methylation may act on mtDNA by similar mechanisms as in nDNA. 154 In mtDNA methylated cytosines are mainly located in non-CpG moieties within the mitochondrial D-Loop, particularly in the promotor region of the heavy strand and in conserved sequence blocks of the which may indicate a role in regulating mtDNA replication or transcription. 155 In addition to cytosine methylation mtDNA also contains hydroxylmethylated cytosine at a higher density than in autosomes in both the D-Loop region and along the entire mitochondrial genome. 155, 156 MtDNA is protein coated and contained within nucleoids. [157] [158] [159] Histone family members, particularly H2A and H2B, have also been observed in mitochondria although rather than directly binding DNA these were found to localise to the mitochondrial membrane. 160 In 2008 Bogenhagen and colleagues 161 found 57 proteins associated with human mtDNA. Amongst these, there are several proteins essential for mitochondrial biogenesis as well as for mtDNA transcription and replication including Mitochondrial transcription factor A, mitochondrial transcription factor B, DNA polymerase gamma, prohibitin, Twinkle helicase and mitochondrial single-stranded DNA binding protein. 159, [162] [163] [164] [165] Whole genome and transcriptome sequencing has also revealed the presence of numerous ncRNAs including siRNAs, miRNAs and lncRNAs which are involved with regulating essential signalling pathways in mitochondria by altering expression of nuclear-encoded mitochondrial proteins. [166] [167] [168] [169] [170] [171] [172] In addition to ncRNAs encoded by nDNA, Rackham and colleagues 173 identified three lncRNAs transcribed by the mitochondrial genome from regions complementary to ND5, ND6 and Cytb genes. These mitochondrial lncRNAs are regulated by the mitochondrial RNase P complex and their abundance varies significantly across different tissue types with a high abundance observed in cardiac tissue. 173, 174 There are also thousands of non-coding small RNAs transcribed by mtDNA the majority of which are derived from sense transcripts of mitochondrial genes, but these have also been mapped to the mitochondrial Dloop region. 175, 176 In addition to external environmental stress, altered metabolic states such as hyperglycaemia in diabetes or uraemia in CKD can also lead to epigenetic changes known as hyperglycaemic or uremic "memory", respectively. 177-179 Epigenetic features are potential therapeutic targets as they may be reversible and tissue specific, therefore they may be attractive potential foci for drugs targeting specific epigenetic changes. For example, epigenetic changes associated with diabetic nephropathy can be reversed by losartan treatment in diabetes mouse models. 123, [180] [181] [182] 
Conclusions
Persistent mitochondrial dysfunction is known to be involved in the initiation and progression of renal diseases, such as acute kidney injury and diabetic nephropathy, resulting from disruption to mitochondrial homeostasis and normal kidney function. 19 Oxidative stress is a common CKD feature and increased production of reactive oxygen species due to mitochondrial dysfunction has been observed in diabetes, inflammation and aging. 183 Increased ROS production due to mitochondrial dysfunction may also contribute to CVD and other co-morbidities associated with CKD. 86, 183, 184 Further investigation into mitochondria roles in maintaining renal health and their contribution to various forms of CKD may unveil new disease mechanisms as well as novel treatments. Significant genetic damage or mutations in NEMGs may also disrupt mitochondrial homeostasis. The cellular machinery and related genes involved in mitophagy, mitochondrial fission, fusion and biogenesis are essential in maintaining mitochondrial homeostasis and dysfunction of these processes may lead to irreversible kidney damage. There is evidence to suggest that mitochondrial dysfunction precedes CKD development, occurring in the early stages of acute kidney injury and diabetic nephropathy, failure to restore mitochondrial function may then initiate the vicious cycles outlined earlier resulting in CKD. 185 The use of multi-omic approaches to investigate CKD are providing valuable insights; the integrated use of these techniques will allow a better understanding of mitochondria influencing in renal disease. PPARGC1A downregulation may be protective adaption to limit ROS production.
Will also reduce expression of downstream targets of NRF-1 and PGC1α and reduce mitochondrial biogenesis and OXPHOS activity.
Downregulation of TFAM may lead to decreased mtDNA copy number.
Expression of NFE2L2, SOD2 and UQCRH may also be associated with increased ROS generation.
Increased expression of Complex I proteins. Complex V proteins and UQCRB may be an attempt to restore OXPHOS mechanisms.
Reduced Complex IV activity may be associated with OXPHOS defects
Increased expression of renal risk variants of APOL1 and NOX4 may increase mitochondrial damage by ROS.
Apoptosis (Intrinsic Pathway)

Downregulated: BCL2L1; AIFM1
Upregulated: BAX; BAK1; HIF1
Reduced expression of BCL-xL allows BAX expression and mitochondrial accumulation to increase which increases apoptosis and depolarises outer mitochondrial membrane in proximal tubular cells. Increased BAX expression also permeabilises the inner mitochondrial membrane leading to cytochrome C release Decreased expression of NRF-1 along with PGC1α will reduce expression of downstream targets of these genes and reduced mitochondrial biogenesis and OXPHOS activity in mitochondria which may be an attempt to reduce ROS production and oxidative stress 2, 4 TFAM Expression regulated by NRF1; Regulates mitochondrial transcription and replication Downregulated in PBMC of CKD undergoing peritoneal dialysis (PD) compared to healthy subjects (p < 0.001) 2 Reduced TFAM expression will alter mitochondrial transcription and replication machinery and reduce the mtDNA copy number 5 
NFE2L2
Transcription factor which regulates the expression of numerous antioxidant/detoxifying enzymes including SOD2 6 Upregulated in PD compared to controls 2 Reduced activity increases oxidative stress and inflammation whereas increased expression may protect against this damage in CKD 7 Increased NFE2L2 expression may protect against oxidative damage and confer anti-inflammatory properties. Mice models have also demonstrated that deletion of this gene may lead to lupus-like autoimmune nephritis 7, 8 Increased expression in CKD may be an attempt to neutralise ROS production 8 
SOD2
Superoxide dismutase (SOD) catalyses the dismutation of superoxide anions to oxygen and hydrogen peroxide -an important antioxidant defence mechanism Upregulated in PD compared to controls 2 Evidence to suggest gene expression is unaffected in CKD but protein content decreased from Stage 1 -4 CKD and then increased again in Stage 5 CKD 9 SOD inactivation may compromise mitochondrial function and reduce mitochondrial biogenesis and reduce antioxidant ability of mitochondria and increase ROS 9 Increased expression in CKD may be an attempt to neutralise ROS production 8 NDUFS5; NDUFA6; NDUFA1; NDUFB1 NADH:Ubiquinone Oxidoreductase Subunit S5; Subunit A6; Subunit A1; Subunit B1 -subunits of Complex I Up-regulated in CKD patients in conservative treatment and HD compared to healthy subjects (p < 0.001, FDR = 1%) 10 Increased expression of components of Complex I may be a compensatory response to dysregulated OXPHOS in an attempt to restore the electrochemical gradient in the outer side of the inner mitochondrial membrane 10 
UQCRH
Ubiquinol-Cytochrome C Reductase Hinge Protein -Complex III Subunit VIII Downregulated in PBMC of CKD undergoing PD compared to healthy subjects (p < 0.001) 2 Up-regulated in PBMC of CKD (stage 4-5) patients in conservative treatment and HD compared to CKD stage 2 -3 and healthy subjects (p < 0.001, FDR = 1%) 10 Downregulation may be a protective response against increased ROS generation and chronic cellular perturbation associated with oxidative injury 2 Upregulation in PBMC may be an attempt to compensate for reduced OXPHOS activity or altered expression due to Haemodialysis treatment) 10 .
Statistically significant difference in mRNA levels of UQCRH between CKD 2-3 and healthy subjects 10 
UQCRB
Ubiquinol-Cytochrome C Reductase Binding Protein -Complex III Subunit VI Up-regulated in PBMC of CKD (stage 4 -5) patients in conservative treatment and HD compared to CKD stage 2 -3 and healthy subjects (p < 0.001, FDR = 1%) 10 Upregulation in PBMC may be an attempt to compensate for reduced OXPHOS activity or altered expression due to haemodialysis treatment) 10 
COX6C; COX7C
Cytochrome c oxidase subunit 6C; subunit 7C -Subunits of complex IV Downregulated in PBMC of CKD patients undergoing PD compared to healthy subjects (p < 0.001) 2 Up-regulated in PBMC of CKD (stage 4 -5) patients in conservative treatment and haemodialysis (HD) compared to CKD stage 2 -3 and healthy subjects (p < 0.001, FDR = 1%) 10 Complex IV activity was significantly reduced in conservative treatment/HD patients and in PD patients compared to healthy subjects which may indicate reduced OXPHOS activity in CKD 2, 10 Higher levels of reactive oxygen species and 8hydroxydeoxyguanosine in CKD stage 4 -5 and HD patients compared to healthy controls which suggests increased oxidative stress in CKD 10 
ATP5I, ATP5J, ATP5O
ATP Synthase, H+ Transporting, Mitochondrial Fo Complex Subunit E (ATP5I); Subunit F6 (ATP5J); O Subunit (ATP5O) -subunits of Complex V Up-regulated in CKD patients in conservative treatment and HD compared to healthy subjects (p < 0.001, FDR = 1%) 10 Increased expression of Complex V components may be a compensatory response to defective OXPHOS. This increased expression may also lead to increased ROS generation and oxidative stress further damaging mitochondria through a vicious cycle MCAD Medium Chain Acyl CoA Dehydrogenase Downregulated in PBMC of CKD undergoing peritoneal dialysis PD compared to healthy subjects (p < 0.001) 2 MCAD catalyzes the first step of mitochondrial fatty acid betaoxidation and is an oxidoreductase enzyme regulated by PGC1-α. Downregulation of this will decrease the breakdown of fatty acid molecules in mitochondria
AIFM1
Codes for Apoptosis inducing factor (AIF) which is a mitochondrial flavoprotein with dual roles in redox signalling and programmed cell death 11, 12 Downregulated in CKD 13 Partial knockdown disrupts mitochondrial bioenergetics, induces mitochondrial fusion and increases mitochondrial ATP content and leads to excess production of ROS. Complete inactivation disrupts complex 1 formation resulting in OXPHOS defects, however, expression of PGC-1α and TFAM was not changed, suggesting that mitochondrial biogenesis is not altered by AIF knockdown 13 
APOL1
Reduces SOD2 and Catalase expression 14 Increased expression of renal risk variants G1 and G2 in various renal complications including CKD 14 Decreased SOD2 may exacerbate mitochondrial damage by ROS 15, 16 G1 and G2 risk variants associated with renal disease amongst the African Diaspora likely due to the protection against African sleeping sickness provided by these PBMC -peripheral blood mononuclear cell; CKD -chronic kidney disease; PD -peritoneal dialysis; HD -haemodialysis; ROS -reactive oxygen species; OXPHOS -oxidative phosphorylation; mtDNA -mitochondrial DNA; ECM -extracellular matrix variants 14, [17] [18] [19] 
NOX4
Main isoform of NADPH oxidase expressed in kidneys Key source of ROS and important component in Redox signalling 20 Up-regulation in CKD associated with AIFM1 deletion 13, 20 Uncontrolled ROS generation may damage mitochondria therefore leading to further ROS production through a vicious cycle 20, 21 
RMND1
Protein encoded by this gene is localized in the mitochondria and involved in mitochondrial translation.
Genetic variants implicated in multisystem failure due to mitochondrial dysfunctionincluding renal complications PD compared to controls [22] [23] [24] [25] [26] [27] [28] Mutations in this gene are associated with combined oxidative phosphorylation deficiency and mitochondrial dysfunction of varying severity -Of the reported cases, seven had renal involvement additional to mitochondrial dysfunction at or earlier than 18 months of age. 3 patients with renal dysfunction where found to be homozygous for a c.1349G>C, p.450Serext*32 stop-extension mutation in RMND1 [22] [23] [24] [25] [26] [27] [28] Science Publishing Group Copyright 2019 www.spg.ltd 24
